​

Design Therapeutics Ownership | Who Owns Design Therapeutics?

OverviewForecastRevenueFinancialsChart

Design Therapeutics Ownership Summary

Design Therapeutics is owned by 44.54% institutional investors, 35.97% insiders, and 19.49% retail investors. Sr one capital management, lp is the largest institutional shareholder, holding 11.48% of DSGN shares. Fidelity Select Biotechnology is the top mutual fund, with 1.45% of its assets in Design Therapeutics shares.

DSGN Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockDesign Therapeutics44.54%35.97%19.49%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Sr one capital management, lp6.53M11.48%$49.14M
Logos global management lp3.65M6.43%$27.52M
Durable capital partners lp3.46M6.12%$334.67M
Point72 asset management3.34M5.88%$25.15M
Conestoga capital advisors3.12M5.52%$301.76M
Jarislowsky, fraser2.89M5.12%$279.97M
Fiera capital2.56M4.53%$248.02M
Primecap management co/ca/2.24M3.96%$216.78M
Mackenzie financial2.13M3.78%$206.81M
Connor, clark & lunn investment management2.05M3.63%$198.72M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Sr one capital management, lp6.53M7.11%$49.14M
Zeno equity partners llp266.28K6.86%$25.79M
Conestoga capital advisors3.12M4.52%$301.76M
Herald investment management230.00K3.65%$22.24M
Summit creek advisors258.25K3.43%$25.01M
Durable capital partners lp3.46M2.75%$334.67M
Almitas capital1.53M2.64%$11.52M
Geneva capital management1.46M2.57%$141.16M
Logos global management lp3.65M2.47%$27.52M
Triasima portfolio management253.85K2.25%$24.58M

Top Buyers

HolderShares% AssetsChange
Point72 asset management3.34M0.04%1.53M
Congress asset management co /ma1.22M0.85%1.22M
Norges bank1.12M0.02%1.12M
Ubs asset management americas690.48K0.02%690.48K
Ra capital management475.70K0.04%475.70K

Top Sellers

HolderShares% AssetsChange
Arrowstreet capital, limited partnership611.83K0.05%-633.32K
Logos global management lp3.65M2.47%-562.63K
Jarislowsky, fraser2.89M1.70%-438.99K
Ecor1 capital---426.68K
T. rowe price investment management1.70M0.10%-379.50K

New Positions

HolderShares% AssetsChangeValue
Congress asset management co /ma1.22M0.85%1.22M$118.30M
Norges bank1.12M0.02%1.12M$108.88M
Ubs asset management americas690.48K0.02%690.48K$66.87M
Ra capital management475.70K0.04%475.70K$3.58M
William blair investment management212.81K0.05%212.81K$20.61M

Sold Out

HolderChange
Fairman group-8.00
Advisor group-10.00
Financial gravity asset management-11.00
Harbour investments-12.00
Spire wealth management-18.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202578-8.24%25,324,931-22.71%441.34%25-35.90%3110.71%
Jun 30, 202590-8.16%34,511,5420.15%601.65%395.41%33-17.50%
Mar 31, 20252-99.51%927,399-98.96%10.01%2-99.00%--100.00%
Dec 31, 20244146.43%88,660,48610.86%1560.78%19813.14%145-2.03%
Sep 30, 20243383.68%65,782,856-1.17%1160.84%160-15.34%12636.96%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Fidelity Select Biotechnology826.43K1.45%-12.70K
Vanguard US Total Market Shares ETF800.90K1.41%-
Vanguard Total Stock Mkt Idx Inv783.62K1.38%-17.28K
iShares Russell 2000 ETF733.61K1.29%-
Fidelity Small Cap Index316.46K0.56%27.00
Vanguard Institutional Extnd Mkt Idx Tr295.05K0.52%-131.22K
State St Russell Sm/Mid Cp® Indx NL Cl C269.86K0.48%-
State St Russell Sm/Mid Cp® Indx SL Cl I269.86K0.47%-
iShares Russell 2000 Value ETF263.30K0.46%-
iShares Biotechnology ETF177.41K0.31%-

Recent Insider Transactions

DateNameRoleActivityValue
Aug 13, 2025William Arsani-Sell$1.14M
Aug 13, 2025William Arsani-Sell$1.81M
Dec 18, 2024Prasad Deepa-Sell$23.86K
Aug 09, 2024William Arsani-Sell$3.46M
Mar 22, 2024Schmid John P.-Buy$33.13K

Insider Transactions Trends

DateBuySell
2025 Q4--
2025 Q3-2
2025 Q2--
2025 Q1--
2024 Q4-1

DSGN Ownership FAQ

Who Owns Design Therapeutics?

Design Therapeutics shareholders are primarily institutional investors at 44.54%, followed by 35.97% insiders and 19.49% retail investors. The average institutional ownership in Design Therapeutics's industry, Biotech Stocks , is 45.22%, which Design Therapeutics falls below.

Who owns the most shares of Design Therapeutics?

Design Therapeutics’s largest shareholders are Sr one capital management, lp (6.53M shares, 11.48%), Logos global management lp (3.66M shares, 6.43%), and Durable capital partners lp (3.46M shares, 6.12%). Together, they hold 24.02% of Design Therapeutics’s total shares outstanding.

Does Blackrock own Design Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Design Therapeutics.

Who is Design Therapeutics’s biggest shareholder by percentage of total assets invested?

Sr one capital management, lp is Design Therapeutics’s biggest shareholder by percentage of total assets invested, with 7.11% of its assets in 6.53M Design Therapeutics shares, valued at 49.14M$.

Who is the top mutual fund holder of Design Therapeutics shares?

Fidelity Select Biotechnology is the top mutual fund holder of Design Therapeutics shares, with 1.45% of its total shares outstanding invested in 826.43K Design Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools